
Capricor Therapeutics (CAPR) Stock Forecast & Price Target
Capricor Therapeutics (CAPR) Analyst Ratings
Bulls say
Capricor Therapeutics Inc has significantly enhanced its valuation of deramiocel for treating Duchenne muscular dystrophy cardiomyopathy, raising it to $2.30 billion from a previous estimate of $794 million, indicating strong market potential for the therapy. The positive results from Phase III clinical trials, particularly the notable improvements in the PUL 2.0 Mid-level Dimension and other clinical metrics, further underscore the efficacy of deramiocel, bolstering investor confidence. Additionally, the company’s continued innovation with its proprietary StealthXTM platform for delivering therapeutics positions it favorably within the biotechnology sector, suggesting strong future financial performance.
Bears say
Capricor Therapeutics Inc. faces a substantial risk associated with the clinical development of its lead product, deramiocel, particularly regarding potential failures in safety, efficacy, and regulatory approval, which could significantly impede progress and market acceptance. The company must also contend with the challenge of declining left ventricular ejection fraction (LVEF) in Duchenne muscular dystrophy patients, which complicates treatment outcomes and may generate volatility in clinical trial interpretations. Furthermore, uncertainties surrounding funding and the potential delays in product launch underscore the fragility of Capricor’s financial outlook, raising concerns about its ability to sustain operations and advance its therapeutic pipeline effectively.
This aggregate rating is based on analysts' research of Capricor Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Capricor Therapeutics (CAPR) Analyst Forecast & Price Prediction
Start investing in Capricor Therapeutics (CAPR)
Order type
Buy in
Order amount
Est. shares
0 shares